Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Alice Tsang Shaw, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA164273 (LIN, JESSICA JIYEONG) Feb 20, 2012 - Feb 28, 2022
    NIH
    Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors
    Role: Co-Principal Investigator
  2. K08CA111634 (SHAW, ALICE T) Jul 6, 2005 - Jun 30, 2010
    NIH
    Ras Signaling in Development and Cancer
    Role: Principal Investigator
  3. T32CA071345 (HABER, DANIEL A.) Aug 1, 1997 - Aug 31, 2023
    NIH
    Training Program in Cancer Biology and Therapeutics
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling HG, Langenbucher A, Schoenfeld AJ, Falcon CJ, Temel JS, Sequist LV, Yeap BY, Lennerz JK, Shaw AT, Lawrence MS, Ou SI, Hata AN, Drilon A, Gainor JF. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clin Cancer Res. 2021 May 15; 27(10):2899-2909. PMID: 33685866.
    Citations:    Fields:    
  2. Felip E, Shaw AT, Bearz A, Camidge DR, Solomon BJ, Bauman JR, Bauer TM, Peters S, Toffalorio F, Abbattista A, Thurm H, Peltz G, Wiltshire R, Besse B. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021 05; 32(5):620-630. PMID: 33639216.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  3. Dagogo-Jack I, Moonsamy P, Gainor JF, Lennerz JK, Piotrowska Z, Lin JJ, Lennes IT, Sequist LV, Shaw AT, Goodwin K, Stevens SE, Do A, Digumarthy SR, Price K, Muzikansky A, Hata AN, Heist RS. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. J Thorac Oncol. 2021 05; 16(5):850-859. PMID: 33545388.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  4. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2020 11 19; 383(21):2018-2029. PMID: 33207094.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  5. Mok T, Peters S, Camidge DR, Noé J, Gadgeel S, Ou SI, Kim DW, Konopa K, Pozzi E, Liu T, Loftin IR, Williams C, Shaw AT. Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. J Thorac Oncol. 2021 02; 16(2):259-268. PMID: 33334571.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  6. Zhang EW, Dagogo-Jack I, Kuo A, Rooney MM, Shaw AT, Digumarthy SR. Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer. Cancer. 2020 10 15; 126(20):4473-4484. PMID: 32757294.
    Citations: 2     Fields:    Translation:Humans
  7. Lin JJ, Langenbucher A, Gupta P, Yoda S, Fetter IJ, Rooney M, Do A, Kem M, Chang KP, Oh AY, Chin E, Juric D, Corcoran RB, Dagogo-Jack I, Gainor JF, Stone JR, Lennerz JK, Lawrence MS, Hata AN, Mino-Kenudson M, Shaw AT. Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. NPJ Precis Oncol. 2020; 4:21. PMID: 32802958.
    Citations: 2     
  8. Gupta M, Concepcion CP, Fahey CG, Keshishian H, Bhutkar A, Brainson CF, Sanchez-Rivera FJ, Pessina P, Kim JY, Simoneau A, Paschini M, Beytagh MC, Stanclift CR, Schenone M, Mani DR, Li C, Oh A, Li F, Hu H, Karatza A, Bronson RT, Shaw AT, Hata AN, Wong KK, Zou L, Carr SA, Jacks T, Kim CF. BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. Cancer Res. 2020 09 15; 80(18):3841-3854. PMID: 32690724.
    Citations: 1     Fields:    Translation:HumansAnimals
  9. Papadopoulos KP, Borazanci E, Shaw AT, Katayama R, Shimizu Y, Zhu VW, Sun TY, Wakelee HA, Madison R, Schrock AB, Senaldi G, Nakao N, Hanzawa H, Tachibana M, Isoyama T, Nakamaru K, Deng C, Li M, Fan F, Zhao Q, Gao Y, Seto T, Jänne PA, Ou SI. U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 09 15; 26(18):4785-4794. PMID: 32591465.
    Citations: 9     Fields:    
  10. Al-Samkari H, Leiva O, Dagogo-Jack I, Shaw A, Lennerz J, Iafrate AJ, Bendapudi PK, Connors JM. Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. J Thorac Oncol. 2020 09; 15(9):1497-1506. PMID: 32437899.
    Citations: 7     Fields:    Translation:Humans
  11. Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, Pérol M, Ou SI, Ahn JS, Shaw AT, Bordogna W, Smoljanovic V, Hilton M, Ruf T, Noé J, Peters S. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020 08; 31(8):1056-1064. PMID: 32418886.
    Citations: 26     Fields:    Translation:Humans
  12. Digumarthy SR, Mendoza DP, Lin JJ, Rooney M, Do A, Chin E, Yeap BY, Shaw AT, Gainor JF. Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements. Cancers (Basel). 2020 Mar 15; 12(3). PMID: 32183422.
    Citations: 2     
  13. Peters S, Shaw AT, Besse B, Felip E, Solomon BJ, Soo RA, Bearz A, Gadgeel SM, Lin CC, Kao S, Seto T, Masters ET, Abbattista A, Clancy JS, Thurm H, Reisman A, Peltz G, Ross Camidge D. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. Lung Cancer. 2020 06; 144:10-19. PMID: 32344248.
    Citations: 1     Fields:    Translation:Humans
  14. Forde PM, Bonomi P, Shaw A, Blumenthal GM, Ferris A, Patel C, Melemed A, Basu Roy U, Ramamoorthy A, Liu Q, Burns T, Gainor JF, Lovly C, Piotrowska Z, Lehman J, Selig W. Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group. Clin Lung Cancer. 2020 07; 21(4):295-307. PMID: 32201247.
    Citations: 1     Fields:    Translation:Humans
  15. Dagogo-Jack I, Yoda S, Lennerz JK, Langenbucher A, Lin JJ, Rooney MM, Prutisto-Chang K, Oh A, Adams NA, Yeap BY, Chin E, Do A, Marble HD, Stevens SE, Digumarthy SR, Saxena A, Nagy RJ, Benes CH, Azzoli CG, Lawrence MS, Gainor JF, Shaw AT, Hata AN. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clin Cancer Res. 2020 06 01; 26(11):2535-2545. PMID: 32086345.
    Citations: 10     Fields:    Translation:HumansCells
  16. Hata AN, Shaw AT. Resistance looms for KRASG12C inhibitors. Nat Med. 2020 02; 26(2):169-170. PMID: 32020086.
    Citations: 9     Fields:    Translation:Humans
  17. Bauer TM, Shaw AT, Johnson ML, Navarro A, Gainor JF, Thurm H, Pithavala YK, Abbattista A, Peltz G, Felip E. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. Target Oncol. 2020 02; 15(1):55-65. PMID: 32060867.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  18. Dagogo-Jack I, Schrock AB, Kem M, Jessop N, Lee J, Ali SM, Ross JS, Lennerz JK, Shaw AT, Mino-Kenudson M. Clinicopathologic Characteristics of BRG1-Deficient NSCLC. J Thorac Oncol. 2020 05; 15(5):766-776. PMID: 31988001.
    Citations: 10     Fields:    Translation:Humans
  19. Mendoza DP, Lin JJ, Rooney MM, Chen T, Sequist LV, Shaw AT, Digumarthy SR. Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer. AJR Am J Roentgenol. 2020 04; 214(4):766-774. PMID: 31887093.
    Citations: 6     Fields:    Translation:Humans
  20. Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, Taylor M, Shaw AT, Montez S, Meric-Bernstam F, Smith S, Tuch BB, Ebata K, Cruickshank S, Cox MC, Burris HA, Doebele RC. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019 Feb; 30(2):325-331. PMID: 31987432.
    Citations:    
  21. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 02; 21(2):271-282. PMID: 31838007.
    Citations: 114     Fields:    Translation:Humans
  22. Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 02; 21(2):261-270. PMID: 31838015.
    Citations: 49     Fields:    Translation:Humans
  23. Gainor JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, Yeap BY, Naidoo J, Khosrowjerdi S, Mooradian M, Lydon C, Illei P, Zhang J, Peterson R, Ricciuti B, Nishino M, Zhang J, Roth JA, Grishman J, Anderson D, Little BP, Carter BW, Arbour K, Sauter JL, Mino-Kenudson M, Heymach JV, Digumarthy S, Shaw AT, Awad MM, Hellmann MD. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression =50. Ann Oncol. 2020 03; 31(3):404-411. PMID: 32067682.
    Citations: 13     Fields:    Translation:Humans
  24. Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019 Jul; 30(7):1121-1126. PMID: 31987379.
    Citations:    
  25. Nishio M, Felip E, Orlov S, Park K, Yu CJ, Tsai CM, Cobo M, McKeage M, Su WC, Mok T, Scagliotti GV, Spigel DR, Viraswami-Appanna K, Chen Z, Passos VQ, Shaw AT. Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. J Thorac Oncol. 2020 04; 15(4):609-617. PMID: 31778798.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  26. Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JC, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SI. Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. Lung Cancer (Auckl). 2019; 10:125-130. PMID: 32009824.
    Citations: 3     
  27. Noé J, Lovejoy A, Ou SI, Yaung SJ, Bordogna W, Klass DM, Cummings CA, Shaw AT. ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials. J Thorac Oncol. 2020 04; 15(4):601-608. PMID: 31712133.
    Citations: 10     Fields:    Translation:Humans
  28. Lin JJ, Schoenfeld AJ, Zhu VW, Yeap BY, Chin E, Rooney M, Plodkowski AJ, Digumarthy SR, Dagogo-Jack I, Gainor JF, Ou SI, Riely GJ, Shaw AT. Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. J Thorac Oncol. 2020 02; 15(2):258-265. PMID: 31669591.
    Citations: 10     Fields:    Translation:Humans
  29. Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2019 12; 20(12):1691-1701. PMID: 31669155.
    Citations: 36     Fields:    Translation:HumansCTClinical Trials
  30. Felip E, de Braud FG, Maur M, Loong HH, Shaw AT, Vansteenkiste JF, John T, Liu G, Lolkema MP, Selvaggi G, Giannone V, Cazorla P, Baum J, Balbin OA, Wang LV, Lau YY, Scott JW, Tan DS. Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study. J Thorac Oncol. 2020 03; 15(3):392-403. PMID: 31634667.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  31. Digumarthy SR, Mendoza DP, Lin JJ, Chen T, Rooney MM, Chin E, Sequist LV, Lennerz JK, Gainor JF, Shaw AT. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer. Clin Lung Cancer. 2020 03; 21(2):153-159.e3. PMID: 31708389.
    Citations: 6     Fields:    Translation:Humans
  32. Ou SI, Gadgeel SM, Barlesi F, Yang JC, De Petris L, Kim DW, Govindan R, Dingemans AM, Crino L, Léna H, Popat S, Ahn JS, Dansin E, Mitry E, Müller B, Bordogna W, Balas B, Morcos PN, Shaw AT. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2020 01; 139:22-27. PMID: 31706099.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  33. Fairclough SR, Kiedrowski LA, Lin JJ, Zelichov O, Tarcic G, Stinchcombe TE, Odegaard JI, Lanman RB, Shaw AT, Nagy RJ. Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort. Exp Hematol Oncol. 2019; 8:24. PMID: 31632838.
    Citations: 1     
  34. Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, Zhong J, Rangachari D, Barbie DA, Phat S, Myers DT, Morris R, Kem M, Dubash TD, Kennedy EA, Digumarthy SR, Sequist LV, Hata AN, Maheswaran S, Haber DA, Lawrence MS, Shaw AT, Mino-Kenudson M, Dyson NJ, Drapkin BJ. Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discov. 2019 10; 9(10):1372-1387. PMID: 31416802.
    Citations: 31     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  35. Katayama R, Gong B, Togashi N, Miyamoto M, Kiga M, Iwasaki S, Kamai Y, Tominaga Y, Takeda Y, Kagoshima Y, Shimizu Y, Seto Y, Oh-Hara T, Koike S, Nakao N, Hanzawa H, Watanabe K, Yoda S, Yanagitani N, Hata AN, Shaw AT, Nishio M, Fujita N, Isoyama T. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun. 2019 08 09; 10(1):3604. PMID: 31399568.
    Citations: 15     Fields:    Translation:HumansCells
  36. Dagogo-Jack I, Rooney M, Lin JJ, Nagy RJ, Yeap BY, Hubbeling H, Chin E, Ackil J, Farago AF, Hata AN, Lennerz JK, Gainor JF, Lanman RB, Shaw AT. Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. Clin Cancer Res. 2019 11 15; 25(22):6662-6670. PMID: 31358542.
    Citations: 18     Fields:    Translation:HumansCells
  37. Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019 07 01; 30(7):1121-1126. PMID: 30980071.
    Citations: 59     Fields:    Translation:HumansCTClinical Trials
  38. Dagogo-Jack I, Awad MM, Shaw AT. BRAF Mutation Class and Clinical Outcomes-Response. Clin Cancer Res. 2019 05 15; 25(10):3189. PMID: 31092613.
    Citations:    Fields:    Translation:Humans
  39. Mendoza DP, Stowell J, Muzikansky A, Shepard JO, Shaw AT, Digumarthy SR. Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis. Clin Lung Cancer. 2019 09; 20(5):339-349. PMID: 31164317.
    Citations: 8     Fields:    Translation:Humans
  40. Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2019 06 01; 37(16):1370-1379. PMID: 30892989.
    Citations: 54     Fields:    Translation:HumansCTClinical Trials
  41. Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. J Thorac Oncol. 2019 07; 14(7):1233-1243. PMID: 30902613.
    Citations: 57     Fields:    Translation:HumansCTClinical Trials
  42. Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, Shaw AT. Clinical Management of Adverse Events Associated with Lorlatinib. Oncologist. 2019 08; 24(8):1103-1110. PMID: 30890623.
    Citations: 12     Fields:    Translation:Humans
  43. Lin JJ, Shaw AT. Refining precision cancer therapy in ALK-positive NSCLC. EBioMedicine. 2019 Mar; 41:9-10. PMID: 30737082.
    Citations:    Fields:    Translation:HumansAnimals
  44. Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, Taylor M, Shaw AT, Montez S, Meric-Bernstam F, Smith S, Tuch BB, Ebata K, Cruickshank S, Cox MC, Burris HA, Doebele RC. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019 02 01; 30(2):325-331. PMID: 30624546.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  45. Dagogo-Jack I, Robinson H, Mino-Kenudson M, Farago AF, Kamesan V, Iafrate AJ, Shaw AT, Lennerz JK. Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. J Thorac Oncol. 2019 05; 14(5):835-843. PMID: 30660796.
    Citations: 1     Fields:    Translation:Humans
  46. Dagogo-Jack I, Rooney M, Nagy RJ, Lin JJ, Chin E, Ferris LA, Ackil J, Lennerz JK, Lanman RB, Gainor JF, Shaw AT. Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. J Thorac Oncol. 2019 05; 14(5):816-824. PMID: 30664990.
    Citations: 18     Fields:    Translation:Humans
  47. Mendoza DP, Dagogo-Jack I, Chen T, Padole A, Shepard JO, Shaw AT, Digumarthy SR. Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class. Lung Cancer. 2019 03; 129:80-84. PMID: 30797497.
    Citations: 7     Fields:    Translation:Humans
  48. Lin JJ, Jiang GY, Joshipura N, Ackil J, Digumarthy SR, Rincon SP, Yeap BY, Gainor JF, Shaw AT. Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases. J Thorac Oncol. 2019 04; 14(4):683-690. PMID: 30529198.
    Citations: 12     Fields:    Translation:Humans
  49. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018 12; 19(12):1654-1667. PMID: 30413378.
    Citations: 118     Fields:    Translation:HumansCTClinical Trials
  50. Dagogo-Jack I, Stevens SE, Lin JJ, Nagy R, Ferris L, Shaw AT, Gainor JF. Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC. J Thorac Oncol. 2018 11; 13(11):e226-e227. PMID: 30368414.
    Citations: 13     Fields:    Translation:Humans
  51. Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Pérol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, Nüesch E, Balas B, Camidge DR. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018 11 01; 29(11):2214-2222. PMID: 30215676.
    Citations: 52     Fields:    Translation:HumansCTClinical Trials
  52. Schrock AB, Welsh A, Chung JH, Pavlick D, Bernicker EH, Creelan BC, Forcier B, Ross JS, Stephens PJ, Ali SM, Dagogo-Jack I, Shaw AT, Li T, Ou SI, Miller VA. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 02; 14(2):255-264. PMID: 30368012.
    Citations: 18     Fields:    Translation:Humans
  53. Piotrowska Z, Costa DB, Oxnard GR, Huberman M, Gainor JF, Lennes IT, Muzikansky A, Shaw AT, Azzoli CG, Heist RS, Sequist LV. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. Ann Oncol. 2018 10 01; 29(10):2092-2097. PMID: 30351341.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  54. Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539. PMID: 30257958.
    Citations: 80     Fields:    Translation:HumansCells
  55. Dagogo-Jack I, Martinez P, Yeap BY, Ambrogio C, Ferris LA, Lydon C, Nguyen T, Jessop NA, Iafrate AJ, Johnson BE, Lennerz JK, Shaw AT, Awad MM. Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clin Cancer Res. 2019 01 01; 25(1):158-165. PMID: 30224342.
    Citations: 17     Fields:    Translation:Humans
  56. Lin JJ, Chin E, Yeap BY, Ferris LA, Kamesan V, Lennes IT, Sequist LV, Heist RS, Mino-Kenudson M, Gainor JF, Shaw AT. Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 01; 14(1):135-140. PMID: 30205166.
    Citations: 19     Fields:    Translation:Humans
  57. Soria JC, Ho SN, Varella-Garcia M, Iafrate AJ, Solomon BJ, Shaw AT, Blackhall F, Mok TS, Wu YL, Pestova K, Wilner KD, Polli A, Paolini J, Lanzalone S, Green S, Camidge DR. Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. Ann Oncol. 2018 09 01; 29(9):1964-1971. PMID: 30010763.
    Citations: 3     Fields:    Translation:Humans
  58. Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discov. 2018 10; 8(10):1227-1236. PMID: 30093503.
    Citations: 67     Fields:    Translation:Humans
  59. Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018. PMID: 30370396.
    Citations: 5     
  60. Farago AF, Taylor MS, Doebele RC, Zhu VW, Kummar S, Spira AI, Boyle TA, Haura EB, Arcila ME, Benayed R, Aisner DL, Horick NK, Lennerz JK, Le LP, Iafrate AJ, Ou SI, Shaw AT, Mino-Kenudson M, Drilon A. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol. 2018; 2018. PMID: 30215037.
    Citations: 31     
  61. Ou SI, Socinski MA, Gadgeel S, Gandhi L, West H, Chiappori AA, Cohen V, Riely GJ, Smoljanovic V, Bordogna W, Wright E, Debusk K, Zeaiter A, Shaw AT. Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer. ESMO Open. 2018; 3(5):e000364. PMID: 30018815.
    Citations: 2     
  62. Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ou SI, Shaw AT, Riely GJ. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. J Thorac Oncol. 2018 10; 13(10):1530-1538. PMID: 29935304.
    Citations: 13     Fields:    Translation:Humans
  63. Chaft JE, Dagogo-Jack I, Santini FC, Eng J, Yeap BY, Izar B, Chin E, Jones DR, Kris MG, Shaw AT, Gainor JF. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer. 2018 08; 122:67-71. PMID: 30032847.
    Citations: 10     Fields:    Translation:Humans
  64. Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018 07; 8(7):822-835. PMID: 29773717.
    Citations: 290     Fields:    Translation:HumansAnimalsCTClinical Trials
  65. Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol. 2018 09 10; 36(26):2693-2701. PMID: 29768119.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  66. Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, Dardaei L, Prutisto-Chang K, Dagogo-Jack I, Timofeevski S, Hubbeling H, Gainor JF, Ferris LA, Riley AK, Kattermann KE, Timonina D, Heist RS, Iafrate AJ, Benes CH, Lennerz JK, Mino-Kenudson M, Engelman JA, Johnson TW, Hata AN, Shaw AT. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018 06; 8(6):714-729. PMID: 29650534.
    Citations: 43     Fields:    Translation:HumansAnimalsCells
  67. McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC. Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 06 15; 24(12):2758-2770. PMID: 29599410.
    Citations: 50     Fields:    Translation:HumansCells
  68. Schapira E, Hubbeling H, Yeap BY, Mehan WA, Shaw AT, Oh K, Gainor JF, Shih HA. Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):624-629. PMID: 29678530.
    Citations: 22     Fields:    Translation:Humans
  69. Dardaei L, Wang HQ, Singh M, Fordjour P, Shaw KX, Yoda S, Kerr G, Yu K, Liang J, Cao Y, Chen Y, Lawrence MS, Langenbucher A, Gainor JF, Friboulet L, Dagogo-Jack I, Myers DT, Labrot E, Ruddy D, Parks M, Lee D, DiCecca RH, Moody S, Hao H, Mohseni M, LaMarche M, Williams J, Hoffmaster K, Caponigro G, Shaw AT, Hata AN, Benes CH, Li F, Engelman JA. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med. 2018 05; 24(4):512-517. PMID: 29505033.
    Citations: 32     Fields:    Translation:HumansAnimalsCells
  70. Drapkin BJ, George J, Christensen CL, Mino-Kenudson M, Dries R, Sundaresan T, Phat S, Myers DT, Zhong J, Igo P, Hazar-Rethinam MH, Licausi JA, Gomez-Caraballo M, Kem M, Jani KN, Azimi R, Abedpour N, Menon R, Lakis S, Heist RS, Büttner R, Haas S, Sequist LV, Shaw AT, Wong KK, Hata AN, Toner M, Maheswaran S, Haber DA, Peifer M, Dyson N, Thomas RK, Farago AF. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. Cancer Discov. 2018 05; 8(5):600-615. PMID: 29483136.
    Citations: 45     Fields:    Translation:HumansAnimals
  71. Hubbeling HG, Schapira EF, Horick NK, Goodwin KEH, Lin JJ, Oh KS, Shaw AT, Mehan WA, Shih HA, Gainor JF. Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 04; 13(4):550-558. PMID: 29378267.
    Citations: 29     Fields:    Translation:Humans
  72. Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. J Clin Oncol. 2018 04 20; 36(12):1199-1206. PMID: 29373100.
    Citations: 76     Fields:    Translation:Humans
  73. Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, Ackil J, Stevens S, Dardaei L, Yoda S, Hubbeling H, Digumarthy SR, Riester M, Hata AN, Sequist LV, Lennes IT, Iafrate AJ, Heist RS, Azzoli CG, Farago AF, Engelman JA, Lennerz JK, Benes CH, Leary RJ, Shaw AT, Gainor JF. Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. JCO Precis Oncol. 2018; 2018. PMID: 29376144.
    Citations: 33     
  74. Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, von Flotow F, Damon LJ, Lee D, Parks M, Dicecca R, Greenberg M, Kattermann KE, Riley AK, Fintelmann FJ, Rizzo C, Piotrowska Z, Shaw AT, Gainor JF, Sequist LV, Niederst MJ, Engelman JA, Benes CH. Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care. Cell Rep. 2017 Dec 12; 21(11):3298-3309. PMID: 29241554.
    Citations: 36     Fields:    Translation:HumansCells
  75. Shaw AT. ALK inhibitors in non-small cell lung cancer: how many are needed and how should they be sequenced? Clin Adv Hematol Oncol. 2017 Dec; 15(12):941-945. PMID: 29315286.
    Citations:    Fields:    Translation:Humans
  76. Gadgeel S, Shaw AT, Barlesi F, Crinò L, Yang JC, Dingemans AC, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Kotb A, Ou SI. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. Br J Cancer. 2018 01; 118(1):38-42. PMID: 29149104.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  77. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018 02; 15(2):81-94. PMID: 29115304.
    Citations: 422     Fields:    Translation:Humans
  78. Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC. Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 2017 10 31; 6. PMID: 29087937.
    Citations: 10     Fields:    
  79. Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017 12; 18(12):1590-1599. PMID: 29074098.
    Citations: 147     Fields:    Translation:HumansCTClinical Trials
  80. Gainor JF, Shaw AT. Fast, Food and Ceritinib in ALK-Positive NSCLC. J Thorac Oncol. 2017 09; 12(9):1341-1343. PMID: 28838710.
    Citations:    Fields:    Translation:Humans
  81. Blackhall F, Ross Camidge D, Shaw AT, Soria JC, Solomon BJ, Mok T, Hirsh V, Jänne PA, Shi Y, Yang PC, Pas T, Hida T, Carpeño JC, Lanzalone S, Polli A, Iyer S, Reisman A, Wilner KD, Kim DW. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open. 2017; 2(3):e000219. PMID: 29209525.
    Citations: 22     
  82. Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, Hubbeling HG, Dardaei L, Farago AF, Schultz KR, Ferris LA, Piotrowska Z, Hardwick J, Huang D, Mino-Kenudson M, Iafrate AJ, Hata AN, Yeap BY, Shaw AT. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2017; 2017. PMID: 29333528.
    Citations: 54     
  83. Lin JJ, Shaw AT. Recent Advances in Targeting ROS1 in Lung Cancer. J Thorac Oncol. 2017 11; 12(11):1611-1625. PMID: 28818606.
    Citations: 38     Fields:    Translation:Humans
  84. Gandhi L, Ou SI, Shaw AT, Barlesi F, Dingemans AC, Kim DW, Camidge DR, Hughes BGM, Yang JC, de Castro J, Crino L, Léna H, Do P, Golding S, Bordogna W, Zeaiter A, Kotb A, Gadgeel S. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. Eur J Cancer. 2017 09; 82:27-33. PMID: 28646771.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  85. Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki S, Ohki E, Usari T, Paolini J, Polli A, Wilner KD, Mok T. Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer. Cancer Res Treat. 2018 Jul; 50(3):691-700. PMID: 28701030.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  86. Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 10; 12(10):1552-1560. PMID: 28689043.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  87. Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017 07; 18(7):874-886. PMID: 28602779.
    Citations: 113     Fields:    Translation:HumansCTClinical Trials
  88. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017 08 31; 377(9):829-838. PMID: 28586279.
    Citations: 462     Fields:    Translation:HumansAnimalsCTClinical Trials
  89. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209. PMID: 28579481.
    Citations: 16     Fields:    Translation:Humans
  90. Dagogo-Jack I, Shaw AT. Expanding the Roster of ROS1 Inhibitors. J Clin Oncol. 2017 08 10; 35(23):2595-2597. PMID: 28520528.
    Citations: 5     Fields:    Translation:Humans
  91. Hsu PP, Shaw AT. Lung Cancer: A Wily Genetic Opponent. Cell. 2017 05 18; 169(5):777-779. PMID: 28525750.
    Citations: 3     Fields:    Translation:Humans
  92. Gainor JF, Shaw AT. J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer. Lancet. 2017 07 01; 390(10089):3-4. PMID: 28501139.
    Citations: 2     Fields:    Translation:Humans
  93. Dagogo-Jack I, Fabrizio D, Lennerz J, Schrock AB, Young L, Mino-Kenudson M, Digumarthy SR, Heist RS, Ali SM, Miller VA, Shaw AT. Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. J Thorac Oncol. 2017 10; 12(10):e155-e157. PMID: 28499860.
    Citations: 1     Fields:    Translation:Humans
  94. Dagogo-Jack I, Lanfranchi M, Gainor JF, Giobbie-Hurder A, Lawrence DP, Shaw AT, Sullivan RJ. A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis. J Immunother. 2017 04; 40(3):108-113. PMID: 28221189.
    Citations: 2     Fields:    Translation:Humans
  95. Alvarez-Breckenridge C, Miller JJ, Nayyar N, Gill CM, Kaneb A, D'Andrea M, Le LP, Lee J, Cheng J, Zheng Z, Butler WE, Multani P, Chow Maneval E, Ha Paek S, Toyota BD, Dias-Santagata D, Santagata S, Romero J, Shaw AT, Farago AF, Yip S, Cahill DP, Batchelor TT, Iafrate AJ, Brastianos PK. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. NPJ Precis Oncol. 2017; 1(1):5. PMID: 29872694.
    Citations: 19     
  96. Dagogo-Jack I, Shaw AT, Riely GJ. Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer. Clin Pharmacol Ther. 2017 May; 101(5):625-633. PMID: 28182271.
    Citations: 7     Fields:    Translation:Humans
  97. Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017 04; 7(4):400-409. PMID: 28183697.
    Citations: 182     Fields:    Translation:HumansCTClinical Trials
  98. Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC. KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 2017 02 01; 6. PMID: 28145866.
    Citations: 35     Fields:    Translation:HumansCells
  99. Lin JJ, Riely GJ, Shaw AT. Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov. 2017 02; 7(2):137-155. PMID: 28122866.
    Citations: 105     Fields:    Translation:HumansAnimals
  100. Lin JJ, Ritterhouse LL, Ali SM, Bailey M, Schrock AB, Gainor JF, Ferris LA, Mino-Kenudson M, Miller VA, Iafrate AJ, Lennerz JK, Shaw AT. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 05; 12(5):872-877. PMID: 28088512.
    Citations: 29     Fields:    Translation:Humans
  101. Dagogo-Jack I, Saltos A, Shaw AT, Gray JE. Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. Am Soc Clin Oncol Educ Book. 2017; 37:619-629. PMID: 28561671.
    Citations: 2     Fields:    Translation:Humans
  102. Lin JJ, Shaw AT. Raising the bar on first-line immunotherapy in lung cancer. Lancet Oncol. 2017 01; 18(1):2-3. PMID: 27932066.
    Citations: 2     Fields:    Translation:Humans
  103. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696. PMID: 27836716.
    Citations: 85     Fields:    Translation:HumansCTClinical Trials
  104. Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 12; 34(34):4079-4085. PMID: 27863201.
    Citations: 53     Fields:    Translation:HumansCTClinical Trials
  105. Shaw AT, Spigel DR, Tan DS, Kim DW, Mehra R, Orlov S, Park K, Yu CJ, Mok T, Nishio M, Scagliotti G, Sutradhar S, Cesic D, Felip E. MINI01.01: Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3: Topic: Medical Oncology. J Thorac Oncol. 2016 11; 11(11S):S256. PMID: 27969450.
    Citations: 2     Fields:    
  106. Temel JS, Shaw AT, Greer JA. Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics. J Clin Oncol. 2016 Oct 20; 34(30):3605-3608. PMID: 27551112.
    Citations: 16     Fields:    
  107. Dagogo-Jack I, Shaw AT. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol. 2016 09; 27 Suppl 3:iii42-iii50. PMID: 27573756.
    Citations: 33     Fields:    Translation:Humans
  108. Campo M, Gerber D, Gainor JF, Heist RS, Temel JS, Shaw AT, Fidias P, Muzikansky A, Engelman JA, Sequist LV. Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. J Thorac Oncol. 2016 11; 11(11):2022-2026. PMID: 27553514.
    Citations: 22     Fields:    Translation:Humans
  109. Lin JJ, Kennedy E, Sequist LV, Brastianos PK, Goodwin KE, Stevens S, Wanat AC, Stober LL, Digumarthy SR, Engelman JA, Shaw AT, Gainor JF. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2016 11; 11(11):2027-2032. PMID: 27544060.
    Citations: 30     Fields:    Translation:Humans
  110. Lin JJ, Shaw AT. Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter? J Clin Oncol. 2016 10 01; 34(28):3363-5. PMID: 27458283.
    Citations: 3     Fields:    Translation:Humans
  111. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133. PMID: 27432227.
    Citations: 268     Fields:    Translation:HumansCells
  112. Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, Mok T, Spigel D, Felip E, Nishio M, Scagliotti G, Branle F, Emeremni C, Quadrigli M, Zhang J, Shaw AT. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. J Clin Oncol. 2016 08 20; 34(24):2866-73. PMID: 27432917.
    Citations: 103     Fields:    Translation:HumansCTClinical Trials
  113. Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM. Clinician Perspectives on Current Issues in Lung Cancer Drug Development. J Thorac Oncol. 2016 09; 11(9):1387-96. PMID: 27401214.
    Citations: 1     Fields:    Translation:Humans
  114. Lin JJ, Shaw AT. Resisting Resistance: Targeted Therapies in Lung Cancer. Trends Cancer. 2016 07; 2(7):350-364. PMID: 27819059.
    Citations: 35     Fields:    Translation:HumansAnimals
  115. Campo M, Al-Halabi H, Khandekar M, Shaw AT, Sequist LV, Willers H. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. Oncologist. 2016 08; 21(8):964-73. PMID: 27354669.
    Citations: 11     Fields:    Translation:Humans
  116. Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, Dias-Santagata D, Clark JW, Engelman JA, Shaw AT, Iafrate AJ. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2016 08; 11(8):1242-1245. PMID: 27343442.
    Citations: 39     Fields:    Translation:Humans
  117. Dagogo-Jack I, Gainor JF, Porter RL, Schultz KR, Solomon BJ, Stevens S, Azzoli CG, Sequist LV, Lennes IT, Shaw AT. Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping. J Thorac Oncol. 2016 09; 11(9):1522-8. PMID: 27296107.
    Citations: 3     Fields:    Translation:Humans
  118. Jänne PA, Kim G, Shaw AT, Sridhara R, Pazdur R, McKee AE. Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle. Clin Cancer Res. 2016 06 01; 22(11):2613-7. PMID: 27250931.
    Citations: 8     Fields:    Translation:Humans
  119. Dagogo-Jack I, Shaw AT. Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics? Oncologist. 2016 06; 21(6):662-3. PMID: 27245570.
    Citations: 11     Fields:    Translation:Humans
  120. Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman JA, Mino-Kenudson M. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016 Sep 15; 22(18):4585-93. PMID: 27225694.
    Citations: 312     Fields:    Translation:HumansCells
  121. Shaw AT, Engelman JA. Crizotinib Resensitization by Compound Mutation. N Engl J Med. 2016 05 05; 374(18):1790-1. PMID: 27144862.
    Citations: 3     Fields:    Translation:Humans
  122. Tan D, Liu G, Kim DW, Thomas M, Felip E, Signorovitch J, Zhang J, Szczudlo T, Shaw AT. 178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC. J Thorac Oncol. 2016 Apr; 11(4 Suppl):S134-5. PMID: 27198316.
    Citations: